NRG Therapeutics

mitochondrial biology, mPTP inhibition, oral small molecules

modulatingsmall molecule

nrgtherapeutics.com·Stevenage, Hertfordshire United Kingdom·$68M total funding

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-MU2K

Projects

ALS/MND mPTP inhibitor discovery program

preclinical

drug program · high · Thu Sep 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Develop mPTP inhibitors as novel treatments for Amyotrophic Lateral Sclerosis / Motor Neurone Disease.

Discovery program applying mitochondrial biology and mPTP inhibition; Target ALS in vivo target validation grant in collaboration with Biospective supports the work.

Awarded non-dilutive Target ALS Foundation funding as one of five 2024 In Vivo Target Validation grant recipients.

Mitochondrial therapeutics platform

undisclosed

platform · medium

Build a pipeline of disease-modifying mitochondrial therapeutics intended to slow or halt progression of neurodegenerative disorders including ALS/MND and Parkinson's disease.

Discovery and development of first-in-class, CNS-penetrant oral small molecules that inhibit the mitochondrial permeability transition pore through a novel mechanism of action.

Company pipeline includes NRG5051, with the lead candidate entering first-in-human testing in 2026.

NRG5051

phase 1

drug program · high

Develop a disease-modifying treatment for neurodegenerative disorders by rectifying mitochondrial function and slowing or halting disease progression.

CNS-penetrant oral small molecule that inhibits the mitochondrial permeability transition pore through a novel mechanism of action.

Lead candidate commenced a first-in-human clinical trial in 2026.

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence